Accendra Health
Accendra Health's revenue rose 3.1% to $2.8 billion in fiscal 2025. Its operating margin was 1.0%, up from −8.1% a year earlier. Free cash flow was −$293 million. It paid out $10 million in dividends and buybacks. The diluted share count rose 0.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Accendra Health does
Accendra Health, formerly Owens & Minor, provides home healthcare equipment, supplies and services in the U.S. Its two brands are Apria and Byram Healthcare. It serves people with diabetes, breathing conditions (including home oxygen and ventilation) and sleep apnea, and supplies ostomy, wound care, urology and incontinence products.
It earns revenue through fee-for-service and capitation arrangements with large government and commercial payors (the insurers and programs that pay for care) for equipment, supplies and services rented and sold to patients. Most items are prescribed by a physician as part of a care plan.
On December 31, 2025, it completed the sale of its Products & Healthcare Services business for an aggregate of $375 million in cash, subject to adjustments, and kept a 5% equity interest in it.
Its biggest risks, as it describes them
- Depending heavily on a few payors, including the recent end of its contracts with a large commercial payor.
- A Medicare decision that could reduce reimbursement for non-invasive ventilation products.
- Losing its relationships with hospital and physician referral sources.
- Relying on certain significant suppliers.
- Risks from the sale of its Products & Healthcare Services business.
Income statement
From fiscal 2016 to 2022, earnings per share fell 26.0% a year and net income 23.2% a year, as new shares raised the share count by 25% and diluted each share's earnings. Accendra Health then lost money in fiscal 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 56 | 70 | 243 | 28 | 282 |
| Debt incl. finance leases | — | 2,501 | 2,098 | 1,841 | 2,050 |
| Net debt (negative means net cash) | — | 2,431 | 1,854 | 1,814 | 1,768 |
| Net debt to EBITDA | — | 6.5x | 5.4x | — | 7.3x |
| Debt to equity | — | 2.6x | 2.2x | 3.1x | — |
| Interest coverage | 7.7x | 1.1x | 1.1x | −2.0x | 0.3x |
| Current ratio | 1.7x | 1.5x | 1.1x | 1.1x | 0.6x |
| Quick ratio | 0.6x | 0.6x | 0.5x | 1.1x | 0.5x |
Cash flow
Projections
Project Accendra Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Accendra Health says to expect
- Full year 2026: net revenue and adjusted EBITDA
The Company expects that full year net revenue will be at the bottom end of the prior outlook range of $2.45 billion to $2.55 billion and that adjusted EBITDA could be as much as 30% lower than the $310 million midpoint of the prior outlook range.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Accendra Health shares on the open market, and 1 insider sold $4,046, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Perry A BernocchiOther | Sold plan | 33,161 | $0.12 | $4,046 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 5 of 9 | 2 of 9 |
| Rule of 40 | −52.1% | 4.7% | −7.5% |
| Altman Z'' | 0.92 | 0.09 | −2.59 |
| Accruals ratio | −14.9% | −10.8% | −28.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Pass | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 4 of 9 | 5 of 9 | 2 of 9 |
Compare
Put Accendra Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Accendra Health | FY25 | 3.1% | 1.0% | −10.6% | 1.2% | 7.3x | 2 | |
| 111 | FY25 | −12.8% | −0.0% | 0.9% | — | — | — | Compare |
| Henry Schein | FY25 | 4.0% | 5.0% | 4.3% | 7.5% | 3.1x | 6 | Compare |
| Medline | FY25 | 11.5% | 7.8% | 4.6% | — | 3.3x | — | Compare |
| Cosmos Health | FY25 | 19.9% | −25.6% | −13.0% | −53.0% | — | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 9,723 | 9,318 | 9,418 | 9,211 | 8,480 | 9,785 | 9,956 | 2,553 | 2,680 | 2,762 |
| Revenue growth | −0.5% | −4.2% | 1.1% | −2.2% | −7.9% | 15.4% | 1.7% | −74.4% | 5.0% | 3.1% |
| Gross profit | 1,187 | 1,172 | 1,070 | 1,128 | 1,281 | 1,513 | 1,826 | 2,125 | 2,219 | 1,289 |
| Research and development | — | — | — | — | — | 12 | 12 | 13 | 13 | — |
| Operating income | 200 | 89 | −352 | 73 | 204 | 368 | 143 | 133 | −218 | 28 |
| Net income | 109 | 73 | −437 | −62 | 30 | 222 | 22 | −41 | −363 | −1,101 |
| Diluted EPS (US$) | 1.76 | 1.20 | −7.28 | −1.03 | 0.47 | 2.94 | 0.29 | −0.53 | −4.73 | −14.31 |
| Diluted shares (millions) | 61 | 60 | 60 | 61 | 64 | 76 | 76 | 77 | 77 | 77 |
| Cash flow | ||||||||||
| Cash from operations | 188 | 57 | 116 | 166 | 339 | 124 | 325 | 741 | 162 | −102 |
| Capital expenditure | 20 | 35 | 45 | 42 | 50 | 41 | 158 | 172 | 170 | 191 |
| Free cash flow | 167 | 22 | 71 | 124 | 289 | 83 | 167 | 568 | −9 | −293 |
| Dividends paid | 63 | 63 | 48 | 5 | 1 | 1 | 0 | 0 | 0 | 0 |
| Share buybacks | 71 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Acquisitions | 0 | 367 | 752 | 0 | 0 | 0 | 1,685 | 0 | 0 | 18 |
| Stock-based compensation | 12 | 12 | 16 | 16 | 20 | 25 | 21 | 14 | 17 | 13 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 186 | 104 | 66 | 67 | 83 | 56 | 70 | 243 | 28 | 282 |
| Debt incl. finance leases | 569 | 917 | 1,677 | 1,572 | 1,037 | — | 2,501 | 2,098 | 1,841 | 2,050 |
| Total assets | 2,718 | 3,376 | 3,774 | 3,643 | 3,336 | 3,537 | 5,386 | 5,093 | 4,656 | 2,452 |
| Total liabilities | 1,758 | 2,361 | 3,255 | 3,181 | 2,624 | 2,598 | 4,441 | 4,169 | 4,070 | 2,913 |
| Shareholders' equity | 960 | 1,016 | 518 | 462 | 712 | 938 | 967 | 945 | 586 | −461 |
| Margins and ratios | ||||||||||
| Gross margin | 12.2% | 12.6% | 11.4% | 12.2% | 15.1% | 15.5% | 18.4% | 83.3% | 82.8% | 46.7% |
| Operating margin | 2.0% | 1.0% | −3.7% | 0.8% | 2.4% | 3.8% | 1.4% | 5.2% | −8.1% | 1.0% |
| Net margin | 1.1% | 0.8% | −4.6% | −0.7% | 0.3% | 2.3% | 0.2% | −1.6% | −13.5% | −39.9% |
| Free cash flow margin | 1.7% | 0.2% | 0.8% | 1.3% | 3.4% | 0.8% | 1.7% | 22.3% | −0.3% | −10.6% |
| Rule of 40 (growth + FCF margin) | 1.2% | −3.9% | 1.8% | −0.9% | −4.5% | 16.2% | 3.4% | −52.1% | 4.7% | −7.5% |
| Return on capital | 9.2% | 5.6% | −14.1% | 2.8% | 9.0% | — | — | 2.5% | −6.6% | 1.2% |
| Return on equity | 11.1% | 7.4% | −57.0% | −12.7% | 5.1% | 26.9% | 2.4% | −4.3% | −47.4% | — |
| Return on assets | 4.0% | 2.4% | −12.2% | −1.7% | 0.9% | 6.5% | 0.5% | −0.8% | −7.4% | −31.0% |
| Net debt to EBITDA | 1.5x | 5.5x | — | 7.9x | 3.2x | — | 6.5x | 5.4x | — | 7.3x |